PYC Physiomics Plc

18 March 2024

Physiomics plc

("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a substantial new contract by an existing large pharma client.  The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178k and it is anticipated that it will be completed over the course of the next six months.

Dr Peter Sargent, CEO, commented: "We are very pleased that we've been awarded this substantial project and we very much look forward to working with the client team on this exciting project".

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.